InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,951.20
(
0.53%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.44
(
0.02%
)
Bitcoin
56,550.19
(
-0.27%
)
Post# of 252525
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

north40000

Send PM Follow Ignore
Followers 253
Posts 17996
Boards Moderated 0
Alias Born 01/19/2006

north40000

Member Level

Re: DewDiligence post# 201449

Wednesday, 05/18/2016 9:58:05 AM

Wednesday, May 18, 2016 9:58:05 AM

Post# of 252525
CNBC interview with Intarcia CEO Kurt Graves[VRTX background] this morning, 5-18-2016:

http://video.cnbc.com/gallery/?video=3000517735

Also Type 2 diabetes that Intarcia hopes to treat with its stabilized Exenatide contained in its implant---note the shelf life emphasized by Graves. FDA filing expected later this year.

A lot of history here. JNJ, Amylin, BMY and now AZN in the background? What is the present story behind older charges of infringement of the Exenatide patent portfolio by the stabilized Intarcia molecule?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up